The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia – are we ready for chemo-free immunotherapy approach?

References

• National Cancer Institute. Surveillance, epidemiology and end results. Cancer stat facts: leukemia – chronic lymphocytic leukemia (CLL), [Internet]. [cited 2019 Dec 25]. Available from: https://seer.cancer.gov/statfacts/html/clyl.html.
   Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174.
   PubMed Web of Science ®Google Scholar
• Shah N, Tam C, Seymour JF, et al. How applicable is fludarabine, cyclophosphamide and rituximab to the elderly? Leuk Lymphoma. 2015;56(6):1599–1610.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382–3391.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014;32(12):1236–1241.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616–5623.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266–1287.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014:370(12):1101–1110.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Klein C, Oya N, et al. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34(2):324–356.
   PubMed Web of Science ®Google Scholar
• Parmelee PA, Thuras PD, Katz IR, et al. Validation of the cumulative illness rating scale in a geriatric residential population. J Am Geriatr Soc. 1995;43(2):130–137.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Dyer MJS, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. Paper presented at: 23rd Congress of EHA; June 14-17; Stockholm, Sweden; 2018.
   Google Scholar
• Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29(7):1602–1604.
   PubMed Web of Science ®Google Scholar
• Freeman CL, Dixon M, Houghton R, et al. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia. 2016;30(8):1763–1766.
   PubMed Web of Science ®Google Scholar
• Autore F, Fresa A, Innocenti I, et al. Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: a monocentric pilot experience. Hematol Oncol. 2019 Dec 26;37:641–643.
   Web of Science ®Google Scholar
• Pejsa V, Lucijanic M, Vrkljan Vuk A, et al. Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 Dec 26;1–6. DOI:10.1080/10428194.2019.1702182.
   Web of Science ®Google Scholar
• Dawson K, Moran M, Guindon K, et al. Managing infusion-related reactions for patients with chronic lymphocytic leukemia receiving obinutuzumab. Clin J Oncol Nurs. 2016:20(2):E41–8.
   PubMed Web of Science ®Google Scholar
• Sarraf Yazdy M, Mato AR, Cheson BD. Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (aristotle, 360 BC)? Blood. 2019;133(2):121–129.
   PubMed Web of Science ®Google Scholar
• Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019:20(1):43–56.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006:24(3):437–443.
   PubMed Web of Science ®Google Scholar
• Velez Lujan J, Lengerke-Diaz PA, Jacobs C, et al. Ibrutinib reduces obinutuzumab infusion related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica. 2019 Dec 27. DOI:10.3324/haematol.2018.212597.
   PubMed Web of Science ®Google Scholar
• The ASCO Post. FDA approves ibrutinib in combination with obinutuzumab in treatment-naive CLL/SLL. [Internet]. [cited 2019 Dec 27]. Available from: https://www.ascopost.com/issues/february-10-2019/fda-approves-ibrutinib/.
   Google Scholar
• Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133:1011–1019.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018:379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Bond DA, Woyach JA. Targeting BTK in CLL: beyond Ibrutinib. Curr Hematol Malig Rep. 2019;14(3):197–205.
   PubMed Web of Science ®Google Scholar
• Ghia P, Pluta A, Wach M, et al. Ascend phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Paper presented at 24th meeting of EHA; June 23-26; Amsterdam, Netherland; 2019.
   Google Scholar
• Rogers KA, Thompson PA, Allan JN, et al. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Paper preseneted at 15th International Conference on Malignant Lymphoma; June 18-22; Lugano, Switzerland; 2019.
   Google Scholar
• Sharman JP, Banejri V, Fogliatto LM, et al. Elevate TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). Paper presented at 61st ASH Annual Meeting and Exposition; December 7-10; Orlando, USA; 2019.
   Google Scholar
• International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–790.
   PubMed Web of Science ®Google Scholar
• European Society for Medical Oncology. FDA approves acalabrutinib for CLL and SLL. [Internet]. [cited 2019 Dec 27]. Available from: https://www.esmo.org/Oncology-News/FDA-Approves-Acalabrutinib-for-CLL-and-SLL.
   Google Scholar
• Eradat H. Venetoclax for the treatment of chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2019;14(5):469–476.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S1, Eichhorst B2, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–778.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Venclyxto; EPAR-product information [internet]. [cited 2019 Dec 27]. Available from: https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf.
   Google Scholar
• Fischer K, Al-Sawaf O1, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019:380(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269–277.
   PubMed Web of Science ®Google Scholar
• Fischer K, Ritgen O, Al-Safaw O et al. Quantitative analysis of minimal residual disease (MRD) shows high rates of undetectable mrd after fixed-duration chemotherapy-free treatment and serves as surrogate marker for progression-free survival: a prospective analysis of the randomized CLL14 trial. Paper presented at 61st ASH Annual Meeting and Exposition; December 7-10; Orlando, USA; 2019.
   Google Scholar
• Tausch E, Bahlo J, Robrehct S, et al. Genetic markers and outcome in the CLL14 trial of the gcllsg comparing front line obinutuzumab plus chlorambucil or venetoclax in patients with comorbidity. Paper presented at at 15th International Conference on Malignant Lymphoma; June 18-22; Lugano, Switzerland; 2019.
   Google Scholar
• Tageted Oncology. Venetoclax/obinutuzumab combo approved by FDA for frontline CLL [internet]. [cited 2019 Dec 28]. Available from: https://www.targetedonc.com/news/venetoclaxobinutuzumab-combo-approved-by-fda-for-frontline-cll.
   Google Scholar
• Food and Drug Administration. FDA approves venetoclax for CLL and SLL. [internet]. [cited 2019 Dec 28]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-venetoclax-cll-and-sll.
   Google Scholar
• Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018:103(5):874–879.
   PubMed Web of Science ®Google Scholar
• Van Sanden S, Baculea S, Diels J, et al. Comparative efficacy of ibrutinib versus obinutuzumab + chlorambucil in first-line treatment of chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Adv Ther. 2017;34(7):1650–1661.
   PubMed Web of Science ®Google Scholar
• Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28(5):1050–1056.
   PubMed Web of Science ®Google Scholar
• Liu D, Zhao J. Frontline therapies for untreated chronic lymphoid leukemia. Exp Hematol Oncol. 2019;8:15.
   PubMed Web of Science ®Google Scholar
• Fürstenau M, Hallek M, Eichhorst B. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. 2019;104(11):2144–2154.
   PubMed Web of Science ®Google Scholar
• Hilal T, Betcher JA, Leis JF. Economic impact of oral therapies for chronic lymphocytic leukemia – the burden of novelty. Curr Hematol Malig Rep. 2018;13(4):237–243.
   PubMed Web of Science ®Google Scholar
• Heltai S, Ghia P, Scarfò L. Relevance of minimal residual disease in the Era of targeted agents. Cancer J. 2019;25(6):410–417.
   PubMed Web of Science ®Google Scholar
• Innocenti I, Autore F, Pasquale R, et al. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2017;10(12):1069–1076.
   PubMed Web of Science ®Google Scholar
• Sinha R, Redekop WK. Cost-effectiveness of ibrutinib compared with obinutuzumab with chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom. Clin Lymphoma Myeloma Leuk. 2018;18(2):e131–e142.
   PubMed Web of Science ®Google Scholar
• Barnes JI, Divi V, Begaye A, et al. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Adv. 2018;2(15):1946–1956.
   PubMed Web of Science ®Google Scholar